PFE - Why Is Moderna Stock Trading Lower Today? | Benzinga
Moderna Inc (NASDAQ:MRNA) shares are trading lower after a longer-term trial analysis revealed a faster decline in the effectiveness of its experimental respiratory syncytial virus (RSV) vaccine.
Citing analysts’ comments, follow-up data from Phase 3 mRNA-1345 Trial At ReSViNET suggests the vaccine efficacy is declining faster than RSV vaccines from GSK Plc (NYSE:GSK) and Pfizer Inc (NYSE:PFE).
Citing two analysts, Reuters noted the data, posted ahead of a conference on RSV next week, that showed mRNA-1345 vaccine efficacy of about 63% after 8.6 months, from 84% at 3.3 months.
Also Read: GSK’s ...